Verastem (United States)

Institution (Company)

Homepage Wikipedia ROR

Also Known As

Verastem (United States)

238

Publications

15.1K

Citations

Authors

Concepts

About

Verastem (United States) is a company institution in Needham, United States known for medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	57	6.8K
2	Cell Biology	13	43	6.5K
3	Immunology	5	9	3.1K
4	Health Sciences	3	16	1.5K
5	Engineering	2	3	66

Verastem (United States)

238

Publications

15.1K

Citations

Page 1

	Year	Citations
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy Hong Jiang, Samarth Hegde, Brett L. Knolhoff, Nature Medicine OncologyPancreatic CancerMedicineReceptor Tyrosine KinaseImmunology	2016	991
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity Alan Serrels, Tom Lund, Bryan Serrels, Cell	2015	405
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL Ian W. Flinn, Peter Hillmen, Marco Montillo, Blood	2018	331
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma Steven M. Horwitz, Raphael Koch, Pierluigi Porcu, Blood	2017	274
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma Ian W. Flinn, Carole B. Miller, Kirit M. Ardeshna, Journal of Clinical Oncology	2019	257
A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK Xiaodong Feng, Nadia Arang, Damiano Cosimo Rigiracciolo, Cancer Cell Hippo PathwaySystems BiologySignaling PathwayGeneticsCancer Genomics	2019	237
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma Vasiliki Panou, Meghana Gadiraju, Arthur Wolin, Journal of Clinical Oncology	2018	222
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer David E. Gerber, D. Ross Camidge, Daniel Morgensztern, Lung Cancer Tumor BiologyMedicineCancer BiologyCancer TreatmentPhase 2	2019	173
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy Carlos J. Díaz Osterman, Duygu Ozmadenci, Elizabeth G. Kleinschmidt, eLife	2019	133
PI3K/mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Cancer Research Tumor BiologyChemoprevention StrategyMedicineIndividual Pi3k IsoformsCancer Cell Biology	2014	128

Page 1